Tagrisso (osimertinib) is typically assessed through CT scans every 3 to 4 months during the first year of treatment, and your oncologist will compare tumor size on those scans to determine whether the drug is shrinking your cancer, holding it stable, or failing to control it. About 73% of patients see their tumors shrink measurably on first-line Tagrisso, and 96% achieve at least disease control, meaning the cancer stops growing even if it doesn’t visibly shrink. But scans are just one piece of the picture. Blood tests, symptom changes, and brain imaging all play a role in building a complete answer.
What CT Scans Tell You
Imaging is the primary tool for measuring Tagrisso’s effectiveness. National guidelines recommend a CT scan after roughly two treatment cycles (about 6 weeks) to get an initial read on how the cancer is responding. After that, scans typically happen every 2 to 4 cycles during active treatment, which works out to roughly every 6 to 12 weeks. Once you’ve been on treatment longer and things look stable, the interval may stretch to every 6 months.
Your oncologist compares tumor measurements across scans using standardized criteria. They’re looking for one of four outcomes: the tumor shrank significantly (partial or complete response), it stayed roughly the same size (stable disease), or it grew (progressive disease). A partial response means the tumor’s longest dimensions have decreased by at least 30%. Stable disease is still a positive sign. It means Tagrisso is keeping the cancer in check, even if the tumors haven’t dramatically shrunk.
If you’re taking Tagrisso as adjuvant therapy (after surgery for earlier-stage lung cancer), the goal is different. There’s no visible tumor left to measure, so scans are watching for any sign of the cancer coming back. In that setting, imaging typically happens at 12 weeks, then 24 weeks, and every 6 months after that for up to five years.
Blood Tests That Track Response
A newer and increasingly useful tool is the liquid biopsy, a blood draw that detects fragments of tumor DNA circulating in your bloodstream. These fragments, called circulating tumor DNA (ctDNA), can reveal whether Tagrisso is working at a molecular level, sometimes before scan results change.
When Tagrisso is effective, the amount of tumor DNA in your blood drops. If it becomes undetectable within the first six weeks of treatment, that’s a strong positive signal. Patients who clear their circulating tumor DNA by that first follow-up tend to have significantly longer progression-free survival and overall survival compared to those who don’t.
The reverse is also informative. If tumor DNA levels start rising, or if new mutations appear in your blood work, that can flag resistance to the drug an average of 2.5 months before the cancer shows visible growth on a CT scan. Not every oncologist orders liquid biopsies routinely, but it’s worth asking about, especially if you want earlier insight into how treatment is going.
Symptom Changes You Can Notice
While scans and blood work provide objective data, your own body gives you real-time feedback. Many patients on Tagrisso notice improvements in their cancer-related symptoms within the first few weeks of treatment. If you had a persistent cough, shortness of breath, chest pain, or fatigue caused by the tumor, gradual improvement in those symptoms is a practical signal that the drug is doing its job.
This isn’t always straightforward, though. Tagrisso has its own side effects, including diarrhea, skin rash, dry skin, and nail changes, that can overlap with or mask symptom improvements. A skin rash, for instance, is common with drugs in this class and has been loosely associated with treatment effectiveness, though that relationship isn’t proven well enough to use as a reliable indicator. The key pattern to watch for is whether your cancer symptoms specifically are improving, staying the same, or worsening, separate from any new side effects the drug itself causes.
How Brain Metastases Are Monitored
Tagrisso crosses the blood-brain barrier more effectively than older targeted therapies, which makes it particularly valuable for patients with brain metastases. In clinical trials, roughly 69% to 87% of patients with measurable brain lesions saw those lesions respond to treatment, and a meaningful percentage achieved complete disappearance of brain tumors on imaging.
If you had brain metastases at diagnosis, your oncologist will schedule dedicated brain MRIs at regular intervals alongside your body CT scans. Improvements you might notice include reduced headaches, better balance, clearer thinking, or resolution of any neurological symptoms that were present before treatment. Even for patients without known brain involvement, the drug’s ability to control the brain as a potential site of spread is part of its overall effectiveness. The estimated probability of developing new brain progression within two years on Tagrisso alone is about 23%, which drops further when combined with chemotherapy.
Signs Tagrisso May Be Losing Effectiveness
Tagrisso works for a median of about 19 months before the cancer finds a way around it, though many patients benefit for significantly longer. When resistance develops, it typically shows up in one of a few ways: tumors start growing again on CT scans, new lesions appear in previously unaffected areas, circulating tumor DNA levels rise, or cancer-related symptoms return or worsen.
At the molecular level, resistance happens through several mechanisms. The most common acquired mutation, called C797S, appears in about 21% of resistant cases. Other pathways include amplification of alternative growth signals that bypass the drug’s target, transformation of the cancer cells into a different type (such as small-cell lung cancer), or the emergence of new driver mutations. Your oncologist may order a tissue biopsy or liquid biopsy at progression to identify the specific resistance mechanism, which helps guide what treatment comes next.
Some patients experience what’s called intrinsic resistance, meaning the drug never really works from the start. If your first scan at 6 to 12 weeks shows clear tumor growth, that’s a signal to reassess the treatment plan promptly.
What a Typical Monitoring Timeline Looks Like
During active treatment for advanced lung cancer, expect visits and blood work within the first 2 to 4 weeks to check for side effects and basic tolerability. Your first response assessment scan usually comes around 6 weeks in. After that, CT scans continue every 2 to 4 months for the first year or two, then potentially less frequently if the cancer remains controlled.
For adjuvant treatment after surgery, monitoring tends to follow a slightly different rhythm: scans at 3 months and 6 months, then every 6 months through year 5, and annually after that. Blood work, including standard labs, typically happens every 3 months throughout treatment regardless of the setting. If your oncologist uses liquid biopsies, those may be drawn at similar intervals or at specific decision points when a clearer molecular picture would help.
Between scheduled assessments, pay attention to new or worsening symptoms like unexplained bone pain, persistent headaches, increasing shortness of breath, or unintentional weight loss. These don’t automatically mean the drug has stopped working, but they’re worth reporting promptly so your team can decide whether earlier imaging is warranted.